Kymera Therapeutics

Kymera Therapeutics, Inc. operates as a biotechnology company, which engages in curing untreatable diseases. It focuses on discovering and developing novel small molecule therapeutics. The firm's proprietary integrated degradation platform consists of informatics-driven target identification, novel E3 ligases and ligands, proprietary predictive modeling, and novel degradation tools. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Kymera Therapeutics reports successful 2022, eyes growth through strategic partnerships

Kymera Therapeutics had a successful year, with promising data in multiple programs and a focus on targeted protein degradation.
The company's financial position is strong, with key goals set for 2023, including collaborations and advancing pipeline programs.
Challenges lie in program prioritization, mechanism of action clarity, and optimizing dosing strategies, while opportunities exist in partnerships and therapeutic innovation.
Overall, Kymera's innovative approach and strategic outlook position it well for growth and continued success in 2023.

Kymera Therapeutics reports solid Q1 performance and eyes clinical milestones

Kymera Therapeutics is progressing well in its pipeline development, focusing on innovative programs with broad enrollment criteria.
Financially, the company is stable with a strong cash position and a clear runway into the future.
While facing challenges in capital allocation and program development, Kymera is actively seeking opportunities for growth and collaboration.

Kymera Therapeutics reports robust earnings, advances in clinical trials

Kymera Therapeutics showcased strong financial performance, progress in clinical trials, and a patient-centric approach to drug development.
While facing challenges in clarity on certain trial aspects and partnership limitations, the company is well-positioned for growth and innovation.
Opportunities lie in expanding clinical studies, developing new INDs, and exploring additional indications for their drug portfolio.

Kymera Therapeutics achieves clinical milestones and financial stability for growth

Kymera Therapeutics has made significant progress in clinical development and financial stability, positioning the company for future growth and success.
The company's focus on genetically validated targets, degrader mechanisms, and combination therapies underscores a strategic and innovative approach to drug development.
While facing challenges in dose optimization and safety standards, Kymera has opportunities to leverage its strengths in solid tumors and immunology for therapeutic advancements.
Overall, Kymera's performance, strengths, and opportunities outweigh the challenges, indicating a promising outlook for the company's future in the biopharmaceutical industry.

Kymera Therapeutics reports robust earnings, advances oral immunology pipeline

Kymera Therapeutics is in a strong financial position with a clear runway for growth, focusing on advancing their oral immunology pipeline and strategic partnerships. They face challenges in prioritizing indications but have opportunities for collaborations and innovative therapeutic development.
The company's progress in clinical programs, including dose escalation trials and milestone achievements, reflects their commitment to advancing novel therapies and addressing unmet medical needs in inflammatory diseases, oncology, and immunology.

Kymera Therapeutics reports solid Q1 performance and eyes program expansion

Kymera Therapeutics had a strong start in 2024 with promising program updates and financial stability.
The company's focus on innovative degrader medicines and potential indication expansion positions it for future growth.
Challenges in data disclosure timing and partnership decisions require strategic navigation for sustained success.
Overall, Kymera's performance, strengths, and opportunities indicate a positive trajectory with key milestones ahead.

Kymera Therapeutics reports strong Q2 earnings and eyes CNS expansion

Kymera Therapeutics showcased strong financial performance, progress in clinical trials, and a focus on innovative drug development approaches.
While facing challenges in market competition and financial management, the company is well-positioned to capitalize on growth opportunities.
Overall, Kymera's emphasis on developing effective oral immunology drugs and exploring CNS indications sets a positive trajectory for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.

Kymera Therapeutics is a protein degradation specialist drug developer with promising Phase 1 and 2 stage protein degraders targeting various diseases. A partnership with Sanofi includes potential milestone payments of up to $1.48 billion for IRAK4 program, showing strong financial backing and support. I am expecting to see Positive data from Phase 2 studies of KT-474 expected in 1H25, with potential for significant share price increase and future M&A opportunities.

Kymera Therapeutics: Solid Progress And No Change To My 'Buy' Rating

Kymera Therapeutics (KYMR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Kymera Therapeutics (KYMR) Surges 23.4%: Is This an Indication of Further Gains?

Sanofi plans to expand phase 2 clinical studies evaluating Kymera's KT-474. This move could accelerate pivotal testing for the potential skin treatment.

Why Kymera Therapeutics Stock Is Soaring Today

Kymera (KYMR) announces expansion plans of ongoing mid-stage studies on KT-474 (SAR444656) by partner Sanofi.

Kymera's (KYMR) Partner SNY to Expand Ongoing HS and AD Studies

Shares of Kymera Therapeutics (KYMR) jumped Tuesday, a day after it said partner Sanofi (SNY) agreed to extend a Phase 2 trial of its experimental drug to treat certain autoimmune skin diseases.

Kymera Therapeutics Soars as Sanofi Expands Studies of Its Skin Diseases Drug

WATERTOWN, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside chat at the UBS Virtual TPD Day on July 15, 2024, at 1:00 p.m. ET.

Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day

WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that following a review of preliminary KT-474 safety and efficacy data by an Independent Data Review Committee, Sanofi has informed Kymera that it intends to expand the ongoing Hidradenitis Suppurativa (HS) and Atopic Dermatitis (AD) Phase 2 trials to more rapidly progress towards pivotal studies.

Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy

KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin's lymphoma

Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including responses in MCC and AML

Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

WATERTOWN, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:

Kymera Therapeutics to Participate in Upcoming June Investor Conferences

Abstract released today highlights safety, pharmacodynamic and clinical response data with additional data to be presented in a poster session on June 1, 2024

Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical studies including an asthma model shared at the ATS Annual Meeting

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting

Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date

Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:

Kymera Therapeutics to Participate in Upcoming May Investor Conferences

BioMarin Pharmaceutical

Blueprint Medicines

Immunovant Inc

Ligand Pharmaceuticals

New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BMRN, BPMC, IMVT, KYMR and LGND well amid volatility.

5 Biotech Stocks Worth Adding to Your Portfolio in 2024

Kymera (KYMR) reports a narrower-than-expected loss in the first quarter. The company expects the current cash balance to provide a runway into the first half of 2027.

Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus

The mean of analysts' price targets for Kymera Therapeutics (KYMR) points to a 34.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict a 34.41% Upside in Kymera Therapeutics (KYMR): Here's What You Should Know

Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Justine Koenigsberg - Vice President, Investor Relations Nello Mainolfi - President and Chief Executive Officer Jared Gollob - Chief Medical Officer Bruce Jacobs - Chief Financial Officer Conference Call Participants Brad Canino - Stifel Nicolaus Eric Joseph - J.P. Morgan Andy Chen - Wolfe Research Divya Rao - TD Cowen & Company Nat Charoensook - Leerink Partners Vikram Purohit - Morgan Stanley Geoff Meacham - Bank of America Kelly Shi - Jefferies Jeff Jones - Oppenheimer Operator Good day, and welcome to the Kymera Therapeutics First Quarter 2024 Results Conference Call.

Kymera Therapeutics, Inc. (KYMR) Q1 2024 Earnings Call Transcript

KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD  with data expected in the first half of 2025

Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update

Kymera Therapeutics (KYMR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

WATERTOWN, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report first quarter 2024 financial results on May 2, 2024, and will host a conference call at 8:30 a.m. ET.

Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2

New preclinical data on novel E3 pairing and structural mechanisms for KT-333, a First-in-Class STAT3 degrader, presented in AACR's late-breaking poster session

Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting

Sanofi

Kymera Therapeutics' shares have dropped from $81 to $39 since my note back in 2021, but have risen >130% in the past 6m. The company's technology targets the ubiquitin proteasome system to degrade disease-causing proteins. Kymera's lead candidate, KT-474, is being developed to treat autoimmune conditions and has shown promising results in Phase 1 studies.

Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith

KT-621 (STAT6) and KT-294 (TYK2) have the potential to provide biologics-like activity  with oral small molecule profiles

Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting

WATERTOWN, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:

News for Kymera Therapeutics Stock (KYMR)